Comparison
SNAP-8 vs. TB-500
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Healing
CAS no.
868844-74-0
no data
Molecular weight
1075.16 g/mol
888 g/mol
Half-life
no data
no data
Sequence
Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2Ac-LKKTETQMechanism of action
SNAP-8
SNAP-8 is an octapeptide variant of Argireline. The sequence corresponds to the N-terminus of the SNAP-25 protein. As with Argireline, the postulated mechanism is competitive inhibition of the SNARE complex needed for acetylcholine vesicle fusion at the neuromuscular endplate. According to the manufacturer the two extra C-terminal amino acids increase SNARE-complex affinity — there are individual industry studies on this but no independent systematic confirmation.
TB-500
Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.
Evidence base
Highest evidence
Human trial
Animal model
Studies
3
3
of which in humans
1
0
Effects recorded
3
4
Open conflicts
0
1
Documented adverse events
1
2